title: Early posttransplant lymphoproliferative disease: clinicopathologic features and correlation with mTOR signaling pathway activation.
abstract: Early posttransplant lymphoproliferative disorders (EPTLDs) represent the first changes in posttransplant lymphoproliferative disorders (PTLDs) morphologic spectrum. EPTLD data are available mostly from case reports and series that include other types of PTLD. Fifteen EPTLDs were reviewed retrospectively. Clinical data, histopathology, clonality, and Epstein- Barr virus (EBV) status were correlated with staining intensity to an antibody for phosphorylated S6 (pS6) ribosomal protein, a downstream effector of mammalian target of rapamycin (mTOR). Median time from transplantation to EPTLD was 50 months (range, 7-135 mo). EPTLDs involved tonsil and/or adenoids (n = 11) and lymph nodes (n = 4), all of which were nonclonal and EBV-encoded RNA-positive. Most (n = 11) were plasmacytic hyperplasia and florid follicular hyperplasia (n = 4). All regressed with reduced immunosuppression, and had increased pS6 staining compared with normal tonsil (P = .002, F test). EPTLDs developed later than previously reported, involved mostly tonsils/adenoids, were EBV-encoded RNA (EBER) positive, showed increased pS6, and had excellent clinical outcome with reduction of immunosuppression.
authors.affiliation: Dept of Pathology, Northwestern University Feinberg School of Medicine, 251 East Huron St, Chicago, IL 60611-2908, USA. bpnelson@northwestern.edu
authors.forename: Beverly P
authors.initials: BP
authors.lastname: Nelson
authors.forename: Kristy L
authors.initials: KL
authors.lastname: Wolniak
authors.forename: Andrew
authors.initials: A
authors.lastname: Evens
authors.forename: Anjen
authors.initials: A
authors.lastname: Chenn
authors.forename: John
authors.initials: J
authors.lastname: Maddalozzo
authors.forename: Maria
authors.initials: M
authors.lastname: Proytcheva
mesh_terms: D000293:Adolescent; D002648:Child; D002999:Clone Cells; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007223:Infant; D008221:Lymphoid Tissue / Q000378:metabolism / Q000473:pathology / Q000821:virology; D008232:Lymphoproliferative Disorders / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D016377:Organ Transplantation / Q000009:adverse effects*; D010766:Phosphorylation; D011183:Postoperative Complications; D016601:RNA-Binding Proteins / Q000378:metabolism; D012189:Retrospective Studies; D038601:Ribosomal Protein S6 / Q000378:metabolism; D012269:Ribosomal Proteins / Q000378:metabolism; D015398:Signal Transduction; D058570:TOR Serine-Threonine Kinases / Q000276:immunology / Q000378:metabolism*; D013997:Time Factors; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D016601:RNA-Binding Proteins; D038601:Ribosomal Protein S6; D012269:Ribosomal Proteins; C067169:RPL22 protein, human; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases